Commentary & Opinion
Access to High-Quality, Low-Cost Antiretrovirals in Developing Countries Major Challenge in Fight Against HIV/AIDS, Opinion Piece Says
August 31, 2007
A "little-noticed milestone was reached in the fight to save lives from AIDS with high-quality antiretroviral treatment" last week when FDA "granted its 50th and 51st priority approvals for HIV/AIDS medications, making them eligible for purchase" by the President's Emergency Plan for AIDS Relief, Ambassador Mark Dybul, who serves as the U.S. global AIDS coordinator and administers PEPFAR, and FDA Commissioner Andrew von Eschenbach write in a Washington Times opinion piece. "One of the many needs that had to be met" in the fight against HIV/AIDS when President Bush announced PEPFAR was for a "supply of inexpensive, high-quality" antiretrovirals, Dybul and von Eschenbach write, adding that in 2004, FDA and HHS "adapted and expedited its review process for generic antiretroviral drugs products" to meet this need. Under the process, "products undergo the same rigorous scientific quality review that would make them eligible for use in the U.S. once patents expire," according to the authors.
Back to other news for August 2007
Health Officials, Policymakers Should Implement HIV Prevention Measures Aimed at Older Adults, Letter to Editor Says
Hospitalizations Among HIV-Positive Infants, Young Children in U.S. Decreasing Because of HAART, Study Says
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.